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Abstract: The human endometrium is a highly regenerative organ undergoing over 400 cycles of
shedding and regeneration over a woman’s lifetime. Menstrual shedding and the subsequent repair
of the functional layer of the endometrium is a process unique to humans and higher-order primates.
This massive regenerative capacity is thought to have a stem cell basis, with human endometrial
stromal stem cells having already been extensively studied. Studies on endometrial epithelial stem
cells are sparse, and the current belief is that the endometrial epithelial stem cells reside in the terminal
ends of the basalis glands at the endometrial/myometrial interface. Since almost all endometrial
pathologies are thought to originate from aberrations in stem cells that regularly regenerate the
functionalis layer, expansion of our current understanding of stem cells is necessary in order for
curative treatment strategies to be developed. This review critically appraises the postulated markers
in order to identify endometrial stem cells. It also examines the current evidence supporting the
existence of epithelial stem cells in the human endometrium that are likely to be involved both
in glandular regeneration and in the pathogenesis of endometrial proliferative diseases such as
endometriosis and endometrial cancer.
Keywords: endometrium; adult stem cells; endometrial regeneration; stem cell markers; endometriosis;
endometrial cancer
1. Introduction
The human endometrium is a highly regenerative organ undergoing over 400 cycles of shedding
and regeneration over a woman’s life time [1–3]. Menstrual shedding, and the subsequent repair of the
endometrial functionalis, is a process unique to humans and higher-order primates [4,5] (Figure 1A,B).
The endometrium re-grows from a mere 1–2 mm thickness after menstrual shedding to 14 mm thickness
in the secretory phase of the menstrual cycle [6], and is able to completely regenerate after parturition,
and in post-menopausal (PM) women when exposed to oestrogen replacement therapy [2,7]. Even after
extensive iatrogenic destructive procedures such as ablation [8], the endometrium regrows in some
women who continue to bleed (25–75%) [9,10]. This huge regenerative ability suggests that the
endometrium has a stem cell basis that supports the tissue maintenance/regrowth.
Prianishnikov was the first to consider the existence of endometrial adult stem cells (ASCs)
and, in 1978, he proposed ASCs to reside in the deeper basalis layer, with their differentiation
marked by functional changes (acquiring) in hormonal receptivity [11]. He suggested a hierarchical
hormone receptiveness in endometrial cells, matching their level of maturity, and therefore, the most
primitive hormone-independent ASCs initially differentiate first into oestrogen-dependent cells,
and then they may further differentiate into both oestrogen and progesterone-dependent cells.
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Terminally-differentiated cells were expected to be only progesterone-dependent, and were postulated
to have a limited lifespan [11] (Figure 2).
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Figure 1. (A): Low power (×100) micrograph of full thickness biopsy of human endometrium and  
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Figure 2. Hormone dependent regulation of the ratio of cell types in the endometrium (Abbreviations 
ST-cell—stem cell, E2-cell—oestrogen sensitive cell, E2P-cell—oestrogen-progesterone sensitive cell, 
P-cell—progesterone sensitive cell). Figure adapted from Reference [11]. 
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This hypothesis proposing that the human endometrium regenerates from the deeper basalis layer
(which is the proposed germinal compartment that persists after menstruation and is responsible for
the regeneration of the new upper/superficial functionalis layer) has been echoed many times [12–15].
Identifying human endometrial epithelial stem cells is problematic due to the lack of specific
markers for isolating and examining them for functional properties [16]. Endometrial epithelial cells
in particular are difficult to culture in vitro for long durations, with the in vivo phenotype of these
cells not maintained using traditional 2D culture methods. For this reason, functional assays that
have been developed to examine the stem cell properties in vitro, may not be suitable for endometrial
epithelial cells. Furthermore, the true and conclusive confirmation of an endometrial epithelial stem
cell requires the demonstration that they are able to produce all of the epithelial cell types that exist in
all regions of the endometrium. However, the characterisation of all different endometrial epithelial
cell subtypes, to ascertain the mature progeny of the putative stem cell, is not yet complete in the
human endometrium.
Early work on endometrial regeneration has been gleaned through scanning electron microscopy
(SEM) studies, this includes some evidence for the existence of endometrial epithelial stem cells. SEM
studies have confirmed that the total regeneration time for postmenstrual surface re-epithelialisation is
approximately 48 h [17] (with the regenerative period beginning between cycle days 2 and 3, and ending
between cycle days 4 and 5). This time interval coincides with the maximum area of the denuded
basalis [17]. The SEM data also suggests that the surface epithelial repair occurs by simultaneous and
progressive outgrowth from the remaining stumps (“mouths”) of basal glands, and by outgrowth from
the surface epithelium, adjacent to the denuded areas, that has not been lost from the isthmic and
cornual regions [17]. A similar observation was reported in rabbit endometrium; the newly restored
surface lining was derived from the intact surface epithelium that remained bordering the artificially
(rabbits do not menstruate) denuded area [18]. The other important findings of the SEM studies are
the descriptions of morphological differences in endometrial epithelial subtypes. For example, ciliated
and non-ciliated cells have been observed in the luminal epithelium (LE) [19]. Cells with the same
morphology as that of endocrine cells were found in the lower layers of the epithelium at late gestation
(clear cells) [20], and are morphologically similar to endocrine cells in other tissues [21]. This further
confirms the existence of different epithelial subtypes that are yet to be characterised for the expression
of distinct markers or for their possible functional diversity.
2. Scope of This Review
In this review, we will examine the evidence for particular markers to delineate the endometrial
stem cell population. We will describe the available evidence under the three main hypotheses that
stem cell marker identification in the endometrium has been undertaken, by:
Identifying markers highly expressed in cells with some in vitro stem cell properties (e.g.,
clonogenic cells, side population (SP) cells).
Identifying markers expressed by cells located in the postulated stem cell niche (basalis and PM
glandular epithelium).
Examining endometrium for the expression of putative stem cell markers identified to be
expressed in epithelial stem cells (ESCs), or other stem cells of different tissues (e.g., OCT4, Mushashi-1,
LGR5, Notch1/Numb).
3. Identifying Markers That Are Highly Expressed in Cells with Some In Vitro Stem Cell
Properties
Stromal ASC work was initiated with identifying markers preferentially expressed in the cell
populations demonstrating higher clonogenic properties in vitro, by Gargett and colleagues [12].
The in vitro colony-forming efficiency assay they used is thought to be a method that enriches stem
cells by inoculating single cell suspensions derived from freshly harvested tissue at low density,
in order to generate colonies from individual cells.
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Endometrial stromal ASCs were also shown to be capable of multi-lineage differentiation into fat,
bone (confirmed with presence of osteopontin, ostenectin and alkaline phosphatase) [22], cartilage,
skeletal muscle [23,24], and smooth muscle (expressing specific smooth muscle cell markers including
alpha-smooth muscle actin (α-SMA), desmin, vinculin and calponin) [25]. Plasticity has also been
shown by the trans-differentiation of endometrial stromal ASCs into neural (neural and glial lineage
markers such as Nestin, NF-L, MAP2, PDGFRa, CNP, Olig2, MBP and GFAP) [24,26], Schwann cells
(expression of S100 and P75 noted) [27], Oligodendrocytes [28], pancreatic cells (shown by secretion
of insulin and markers of β cells such as PDX1, proinsulin and c-peptide) [29,30], urinary bladder
epithelial cells (urothelium, as tested by urothelium-specific genes and proteins, uroplakin-Ia/Ib, II, III
and cytokeratin 20) [31], hepatocytes (biomarkers albumin and cytokeratin 8, reduced α-fetoprotein
and α-SMA expression, synthesised urea, and stored glycogen) [32,33], and megakaryocytes (identified
by expression of CD41a and CD42b and reduction of pluripotent transcription factors Oct4 and Sox2,
platelets were seen as functional as evidenced by the upregulation of CD62p expression and fibrinogen
binding following thrombin stimulation), both in vitro and in animal models [34,35].
Studies employing animal models of Duchenne muscular dystrophy [36], stroke [37], diabetes [38],
Parkinson’s disease [39,40], and critical limb ischemia [41] have suggested that endometrial stromal
ASCs improve outcomes, postulating an in vivo differentiation potential for these cells.
Further in vitro stem cell properties that were utilised to identify endometrial ASCs include
examining the side population (SP) cells and label retaining cells (LRC) as detailed below.
3.1. Markers Identified in Clonogenic Cells
3.1.1. CD146 and Platelet Derived Growth Factor–Receptor β Co-Expression
The first markers proposed to identify an endometrial stromal ASC population were CD146
and platelet-derived growth factor–receptor β (PDGF-Rβ) (2 perivascular cell markers) [22]. This is
because their co-expression was detected in cells with higher clonogenic ability in vitro. These cells
were located in the perivascular area in both the functionalis and the basalis of the intact full thickness
human endometrium [42]. In vitro FACS sorted CD146+/PDGF-Rβ+ cells had significantly greater
colony-forming capabilities than CD146−/PDGF-Rβ− cell populations (7.7 ± 1.7% versus 0.7 ± 0.2%
respectively) [42]. CD146+/PDGF-Rβ+ cells produced more large colonies with densely packed cells
and a high nuclear:cytoplasmic ratio. The CD146+PDGF-Rβ+ cells expressed typical mesenchymal
stem cell (MSC) surface markers such as CD29, CD44, CD73, CD90 and CD105, and were negative for
haematopoietic (CD34, CD45) and endothelial markers (CD31) [42]. When cultured in appropriate
induction media, the CD146+PDGF-Rβ+ cells underwent multi-lineage mesenchymal differentiation
into adipogenic, myogenic, chondrogenic, and osteoblastic lineages [42]. However, these studies
used pooled, clonally-derived CD146+PDGF-Rβ+ cells (not singly expanded clones) and did not use
positive control cells with known multi-lineage differentiation potential (such as human mesenchymal
stem cells (hMSCs)) to determine their true differentiation ability. Apart from the colony-forming
capacity, and multi-lineage differentiation ability, the authors did not examine other stem cell-related
features and functions of the CD146+PDGF-Rβ+ cells. Therefore, we are not able to comment on
their capacity to produce endometrial stroma either in a more physiologically relevant 3D culture
in vitro, or their in vivo tissue reconstitution ability. Therefore, it is difficult to decisively conclude that
these cells are an ASC population that regenerates the endometrial stroma. However, it is thought
that the CD146+PDGF-Rβ+ subpopulation are similar to bone marrow and adipose tissue MSCs in
their differentiation potential, and their perivascular location is also shared by MSCs in many other
organs [43].
3.1.2. SUSD2
Sushi domain containing-2+ (SUSD2+) (also known as W5C5) was the next endometrial stromal
ASC marker to be reported and it was particularly successful in selecting endometrial MSCs [44].
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SUSD2+ cells represented 4.2 ± 0.6% of the freshly sorted endometrial stromal cells using flow
cytometry, and assumed a peri-vascular location both in the basalis, and functionalis, with a
significantly greater clonogenicity (median 3.6: range, 0.7–6.9) than depleted counterparts (median 0.6:
range, 0.1–3.8). W5C5+ cells were able to be differentiated into adipocytes, osteocytes, chondrocytes,
myocytes, and endothelial cells (no MSCs were used as an external control), producing endometrial
stromal-like tissue in vivo. SUSD2+ cells were transplanted under the kidney capsule of non-obese
diabetic, severe combined immunodeficiency mutation and interleukin-2Rγ allelic mutation (NSG)
mice, and white growths (small masses) were identified macroscopically on 2 out of 10 kidneys. When
the mice were examined by histological and microscopic analyses, stromal-like connective tissue was
revealed under all of the kidney capsules. The SUSD2+ cells produced significantly greater numbers of
CFUs and the study identified SUSD2+ as a single marker capable of purifying endometrial MSCs [44],
thus negating the need to use two markers (CD146+/PDGF-Rβ+) that were proposed in the earlier
studies. Although there was a considerable overlap of SUSD2 expression with CD146+PDGF-Rβ+
expression, the co-expression of the markers was not consistent. Moreover, endometrial pericytes are
postulated to express CD146+/PDGF-Rβ+ whilst perivascular location is proposed for the SUSD2+
cells suggesting some dissimilarities between the cells identified by these markers [15].
3.2. Side Population Cells
SP analysis distinguishes stem and progenitor cells from other more differentiated, somatic cells
based on their ability to extrude DNA-binding fluorescent dyes (such as Hoechst 33342, a fluorescent
dye that binds to the minor groove of deoxyribonucleic acid) since they express special ATP-binding
cassette–containing pumps (ABC transporters—a type of membrane-bound active transporter, ABCG2).
SP cells (0–5%) have been identified in fresh isolates [45–47] and short-term cultures [48] of human
endometrial cells. The percentage of SP cells in single cell endometrial suspensions (derived from
different patient samples) was reported to be highly variable between individuals. However, higher
numbers seemed to be found in the menstrual [48] and proliferative [45,47] stages of the cycle.
This variability was also mirrored by CFU activity in human endometrium. There is no consensus yet on
whether the absolute number of SP cells are stable throughout the menstrual cycle or not. In agreement
with the hypothesis that ASCs constitute a small, quiescent and static resident population [47],
the decline of SPs in the secretory phase may result from dilution as the functionalis grows and
increases in thickness. When SP cells (freshly sorted) showed little growth in culture, the authors
argued that this was secondary to them being quiescent (most of the cells (85%), being in G0 phase of
the cell cycle). This is a proposed feature of ASCs, but, in contrast, the SP cells sorted from endometrial
short-term cultures were, primarily, in G1 and G1/M/S phases [45]. Endometrial SP cells sorted from
short-term cultures did not express endometrial epithelial (CD9), or stromal (CD13) cell differentiation
markers to start with, but these markers were re-expressed in subsequent long-term Matrigel cultures,
indicating a capacity to differentiate into CD9+E-cadherin+ gland-like organoids (suggesting epithelial
differentiation) and CD13+ stromal clusters when cultured for a further 2 months on collagen-coated
dishes [48]. However, even FACS, the most efficient sorting method available, does not have 100%
efficiency/purity in sorting these cells. Therefore, particularly in long-term culture, a small percentage
of both epithelial and stromal cells that are likely to have been contaminating the initial SP (although
the authors reported that they do not express measurable levels of epithelial/stromal markers) may
have expanded. The other reports examining the endometrial SP cells show SP cells in both the stromal
and epithelial populations [1,47,49]. Furthermore, it is known that endometrial cells in 2D culture
undergo culture-related changes and loss of cellular phenotypical markers and thus, cultured cells
may lose their markers, but they have the capacity to regain them in a more physiologically relevant
growth environment, the 3D matrix. Finally, the achievement of a single cell suspension from solid
tissue samples (necessary for cell sorting (e.g., enzymatic digestion)) will remove the cell surface
proteins, which will later be re-formed in cells with prolonged culture. All these issues need to be
considered when interpreting the current literature. The sorted short-term cultured SP cells were able
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to be maintained in culture for 3 months, whereas the non-SP cells sorted from the short-term cultured
SP cells became senescent within 3 months [48]. This evidence concurs with the longevity associated
with ASCs as opposed to differentiated cells.
To demonstrate their functional potential, cultured endometrial SP cells were shown to decidualise
after being treated with oestradiol and progesterone, therefore confirming their ability to assume the
morphologic, functional, and known terminal differentiation changes characteristic of the secretory
endometrium [45].
Additionally, by differentiating into adipocytes and osteoblasts in vitro, endometrial epithelial
SP cells have been shown to be multipotent, however, once again the differentiation potential was
not compared with a control stem cell type such as hMSCs [1]. After 2 weeks in culture, the authors
reported the presence of Oil Red O lipid vacuoles in adipogenic induction media (but the round
morphology typical of adipocytes was not seen). Similarly, in osteogenic induction media, positive
immuno-reactivity for bone sialoprotein was reported. This evidence is intriguing and needs to be
considered with the possibility of contamination with stromal cells (which are known to have the ability
to differentiate in the mesenchymal lineages). Further evidence has been produced by Kurita et al.,
with their elegant set of xenograft experiments demonstrating the adult endometrial epithelium to be
lineage specific [50].
Masuda et al., demonstrated unipotency of the endometrial epithelial SP cells in vitro by injecting
them under the mouse kidney capsule (mesodermal derivative), and generating endometrial tissue;
those cells did not differentiate into kidney parenchyma [44]. This unipotency was echoed with work
showing that SSEA-1 positive endometrial cells grown in a chimeric explant model, using kidney
tissue isolated from CD1 neonatal mice, injected under the kidney capsule, produced endometrial
gland like structures staining positive for endometrial differentiation markers [51].
Serum oestradiol levels have been shown to change in the same manner as the proportion of SP
cells in postpartum mice, perhaps indicating that oestrogen is a prerequisite for increasing the size of SP
cells populations [52]. This finding of increased oestrogen was confirmed within a mouse endometrial
injury model; stromal SP cells significantly increased 6 h after injury, but they were dependent on
oestrogen, not progesterone nor a combination of oestrogen and progesterone [53].
A relationship between stromal and epithelial ASCs was seen when stromal SP cells were
transplanted under the kidney capsule in mice; only endometrial stroma was formed. When epithelial
SP cells were transplanted, only epithelium was formed. Endometrial-like tissue was only generated
when both these populations were combined. This observation would support the existence of two
distinct ASCs—a stromal and an epithelial ASC [49].
3.3. Markers Identified in Cells with Other MSC Properties
3.3.1. Menstrual Blood-Derived Stem Cells
Another functional assay to identify stem cells is their ability to differentiate in to a variety
of cell types, i.e., the differentiation potential. In 2007, it was reported that menstrual blood
could be used to obtain endometrial stromal ASCs, and these were capable of differentiation into
adipocytes, osteoblasts, chondrocytes, cardiocytes, myocytes, and endothelia [54]. These menstrual
blood-derived stromal ASCs (mbdASCs) were also capable of trans-differentiation into endodermal
and ectodermal tissue, such as hepatocytes, pulmonary epithelia and neurones. The mbdASCs were
mononuclear, and demonstrated positive immuno-reactivity for CD90, CD73, and CD103, but were
devoid of CD34 and CD45, suggesting the cells are of mesenchymal, not haematopoietic in origin [54].
The differentiation potential of these cells was compared to cord blood-derived MSCs, by comparing
the expression of proteins related to stem cell function. Matrix metalloproteases (MMP-3 and MMP-10),
cytokine growth factors (GM-CSF, PDGF-BB) and angiogenic factors (ANG-2) were shown to be
expressed by the mbdASCs at higher levels than the cord blood-derived MSCs, suggesting that
the mbdASCs have similar phenotypical features to ASCs, but differences in their function exist.
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mbdASCs are an attractive target as a treatment for many diseases, due to easy access, non-invasive
collection and, if there is a potential therapeutic use, their possible autologous utility will deem
them superior to many other ASC types [55]. The use of autologous cells for the subacute phase
of stroke offers a practical clinical application [56]. When grown in appropriate conditioned media,
the mbdASCs express neuronal phenotypic markers (Nestin, MAP2), and in an in vitro stroke model of
oxygen and glucose deprivation it was found that oxygen and glucose deprived-exposed primary rat
neurons, (co-cultured with mbdASCs or exposed to the media collected from cultured menstrual blood),
exhibited significantly reduced cell death [55]. Transplantation of mbdASCs (either intra-cerebrally,
or intravenously, and without immunosuppression) into a rat model of ischaemic stroke, significantly
reduced behavioural and histological impairments, compared to vehicle-infused rats, supporting
the use of mbdASCs as a stem cell source for cell therapy in stroke [55–58] and other basal ganglia
disorders, such as Parkinson’s and Huntington’s disease [59].
Sepsis (in the cecal ligation and puncture mouse model) has also been shown to have improved
outcomes when mbdASCs are utilised in the treatment regime, alongside antibiotics. mbdASCs,
in synergy with antibiotics, improved the survival rate (95%) in comparison; with saline (6%);
antibiotics alone (73%); and mbdASCs alone (48%); concluding that mbdASCs could constitute a
feasible approach for the future clinical treatment of sepsis [60].
A mouse model of premature ovarian failure, treated with mbdASCs, expressed higher levels of
ovarian markers (AMH, inhibin α/β and FSH receptor), and the proliferative marker Ki67. In addition,
the overall weight, plasma oestrogen level, and number of normal follicles increased overtime
compared with controls [61].
mbdASCs have been differentiated into hepatocyte-like cells, and demonstrated in vitro mature
hepatocyte functions such as urea synthesis, glycogen storage, and indocyanine green uptake; showing
their potential to be used in chronic liver disease management [62–64].
The type 1 diabetes mellitus mouse model was used to show the therapeutic effects of
mbdASCs on the mechanism of β-cell regeneration after transplantation [38]. The mbdASCs
reversed hyperglycaemia and weight loss, prolonged lifespan, and increased insulin production
in the diabetic mice. The mice recovered islet structures and increased their β-cell number, with the
majority of the mbdASCs migrating into the damaged pancreas, and being located at the islet, duct,
and exocrine tissue. The mbdASCs were found to enhance neurogenin3 expression (represents
endocrine progenitors) rather than differentiate into insulin-producing cells, concluding that they
stimulated β-cell regeneration through promoting differentiation of endogenous progenitor cells [38].
mbdASCs have also been proposed to be used for bone tissue-engineering purposes (taking
advantage of their osteogenic driving potential) [65]; dermatological lesions and diseases [66]; heart
muscle repair [67]; limb ischaemia [41]; and muscular dystrophy [68].
More recently, it has been shown that these mbdASCs have the ability to secrete decidualisation
markers (prolactin and insulin-like growth factor binding protein-1), and differentiate into decidualised
cells, leading to the potential of a therapy for decidualisation insufficiency [69]. When cultured in
differentiation-inducing media supplemented with 20% human follicular fluid, the human mbdASCs
form oocyte-like cells and express germ cell markers. Cells also expressed FSH and LH receptors,
and produced oestrogen and progesterone regulated by gonadotrophin, suggesting a potential to
differentiate in to ovarian tissue [70]. The exact origin of these cells (endometrial or bone marrow
derived), however, is not known. Another further important consideration is that most diseases for
which stem cell therapy has been proposed (e.g., prolapses, strokes, myocardial infarctions) occur in
older, PM women who do not menstruate. The regenerative ability of the PM endometrium may allow
stem cell harvesting after hormone treatment, yet the effect of such a treatment can be detrimental on
the health of an elderly patient with cardiovascular disease and other comorbidities. Therefore, these
practical challenges need to be considered when pursuing menstrual blood as a source of stem cells for
autologous therapeutic avenues.
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3.3.2. Bone Marrow as a Source of Endometrial ASCs
Bone marrow, as a source of endometrial regeneration, is supported by the ability of bone
marrow-derived MSC to produce ‘decidua-like’ stroma, after activation of the protein kinase
cAMP-dependent pathway in vitro [71]; together with bone marrow-derived cells being found in
the decidua of normal murine pregnancy [72]. Stem cells of bone marrow origin typically express
markers such as CD34. Co-culture of bone marrow-derived cells with endometrial stromal cells, and
oestrogen stimulation, result in their differentiation into CK+ endometrial epithelial-like cells [73].
When male bone marrow-derived cells were transplanted into female mice, Fluorescence in
situ hybridisation demonstrated the Y-chromosomes to be present only in 0.0002% of CD45-/F4/80-
epithelial cells, and 0.0003% of CD45-/F4/80- stromal cells of the endometrium [74]. In another
set of experiments, samples from female mice harvested 40 days after a haematological stem cell
transplant, showed an average of 6% donor-derived cells in the endometrium, concluding that bone
marrow-derived endothelial progenitors contribute to the formation of new blood vessels in the
endometrium [75].
In a study of Human leucocyte antigen mismatch transplants, donor-derived endometrial cells
were detected in endometrial biopsy samples from all bone marrow recipients, and accounted for a
wide range (0.2 to 48%) of epithelial (displaying CD9 marker), and vimentin positive stromal cells
(0.3 to 52%) [76–78]. SP cells were not shown to be formed by XY donor-derived cells [77].
Therefore, the evidence presented above may suggest bone marrow to also be a source of stem
cells for endometrial regeneration, but its contribution seems to be low. It is likely that bone marrow
could be implicated in endometrial repair after times of massive injury, such as ablation, and in the
formation of the decidua; when the endometrium requires ‘extra-assistance’.
In a more recent study, authors using chimeric mouse endometrial tissue reconstitution with bone
marrow derived from transgenic mTert-green fluorescent protein (GFP) reporter mice and irradiated
recipients have suggested that bone marrow stem cells do not contribute to any of the endometrial
cell lineages such as stroma, epithelium or endothelium [79]. All of the cells that were detected in
the endometrium were immune cells expressing the pan-leukocyte marker CD45, including CD3+
T cells and F4/80+ macrophages; that immuno-stained weakly for CD45. The macrophages were
abundant in the stroma, infiltrating the epithelial and vascular compartments, and it was noted that
they could easily be mistaken for bone marrow-derived endometrial cells. The authors concluded
(in disagreement with previous studies) that bone marrow cells are unlikely to transdifferentiate
into endometrial stroma, epithelium and endothelium. They warned of the massive implications,
since bone marrow-derived endometrial stem cells have been anticipated to be useful for numerous
treatment strategies discussed previously [79]. Further work to clarify this possibility is urgently
needed before their clinical applications.
3.4. Label Retaining Cells
Locating LRC in animals (the use of the LRC technique in humans is not permitted due to
BrdU being a recognised health hazard) is a method of identifying somatic stem/progenitor cells
and their location in the stem cell niche, when specific markers are unknown. This method relies
on the infrequent cell turnover of most ASCs, in comparison to rapidly proliferating TA cells [2,80].
Mouse endometrium was pulse labelled with BrdU and studied after an 8-week chase to identify
endometrial LRC.
3.4.1. Epithelial LRCs
Gargett’s group reported that 3% of the epithelial nuclei were BrdU+ and were located in the
LE. They were shown not to express ERα through dual labelling IF, providing evidence that LE
stem/progenitor cells are responsible for the growth of glands during development and in cycling
mice [80]. In ovariectomised prepubertal mice, the first cells to proliferate in oestrogen-stimulated
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endometrial growth differed from ovariectomised cycling mice, in the first, the epithelial LRC
proliferated, suggesting they function as stem/progenitor cells to initiate epithelial regeneration;
while in the latter, epithelial LRC and non-LRC rapidly proliferated to regenerate LE and glandular
epithelium [80]. Using a mouse model with menstrual breakdown and repair, ERα negative
glandular epithelial LRC contributed to the repair of the LE following menstruation, post progesterone
withdrawal [81]. Endometrial repair occurred in the absence of oestrogen [81]. BrdU+ epithelia was
lost soon into the chase period, leading to the thoughts that the epithelial regeneration could be relying
on the self-duplication of a mature epithelial cell type, or that the LRC technique is not sensitive
enough to label rare endometrial epithelial cells with an ASC phenotype [82].
3.4.2. Stromal LRCs
Between 6–9% of the stroma were LRCs and they were located just below the LE at the
endo-myometrial junctions or near the blood vessels [80,82], with 84% of them being ERα negative.
These cells were found to not be leucocytes (by excluding CD45 staining), or endothelia (CD31
staining) [80]. BrdU+ cells surrounding blood vessels were positive for α-SMA, making it probable
that these cells represent pericytes. In some studies, 0.6% of stromal LRCs co-expressed OCT4
(a pluripotency marker) and c-kit (a haemopoietic stem cell marker) [82], so, they were potentially in
an undifferentiated state; but in others, neither Sca-1 [80] nor c-kit [83] were expressed. However, to
date, there are no studies describing cells co-expressing the classical triad of OCT4, NANOG and SOX2
confirming pluripotency, in the human endometrium.
Oestrogen was shown to drive epithelial LRC proliferation in juvenile development, but had a
minimal role in epithelial and stromal LRC cyclical regeneration, perhaps indicating that adjacent
BrdU−/ERα+ endometrial cells release paracrine factors to mediate an LRC response [81].
4. Identifying Markers That Are Expressed by Cells Located in the Postulated Stem Cell Niche
(Basalis and PM Glandular Epithelium)
Unlike stromal studies, the studies on epithelial stem cell markers considered the hypothesis that
the stem cells should reside in the basalis glands, or in the PM epithelium (Figure 1B). The basalis
markers described below (SSEA-1, nuclear SOX9, nuclear β-catenin) were the first basalis markers
to be presented as epithelial ASC markers in 2013 [13]. Subsequent work has also suggested
N-cadherin to be another basalis marker [84], but the very recent work using LGR5 in situ hybridisation
challenges this hypothesis and proposes the existence of more than one epithelial stem cell niche in
the human endometrium [85]. These studies, however, are based on the presumption that human
endometrial glandular architectural arrangement is a single blunt-ended tube, which is disputed in 3D
reconstruction studies [86]. The Nguyen et al., study, in particular, suggests that cells deeper in the
glandular base are more likely to be marking the more primitive cell, i.e., a hierarchical arrangement
depending on the cellular location within the presumed single tubular, blind-ended glandular
structure [84]. Hence, the localisation of these need to be re-examined with the 3D architectural
re-modelling of the endometrial glands to fully appreciate the cellular hierarchical arrangement and
stem cell organisation of the human endometrial epithelial compartment. In the stroma, only a limited
number of stem cell markers have been examined on the basis of their abundance in the postulated
stromal stem cell niche, the perivascular region.
4.1. SSEA-1
SSEA-1 is a cell surface glycan, an antigenic epitope, defined as Lewis X carbohydrate,
and is expressed by preimplantation mouse embryos, teratocarcinoma stem cells, and mouse
ESCs [87–90]. Its presence signifies cells in an undifferentiated state, as expression is lost during
stem cell differentiation.
In the human endometrium, immuno-reactivity to SSEA-1 is specific to epithelia and some
leucocytes only [13]. Intensity is significantly greater in the epithelium of the proliferative over the
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secretory phase, and strongest in the basalis, and basalis-like PM endometrium, when compared with
the functionalis epithelium. SSEA-1 enriched cell population has a greater propensity to produce
gland-like structures in 3D culture, and also has higher telomerase activity and longer telomere lengths.
The function of SSEA-1 in the endometrium remains unknown, but it is postulated to be associated
with cell adhesion, migration, and capacity to differentiate [13].
Fibroblast growth factor (FGF) and Wnt-1 are both involved in stem cell maintenance and
differentiation; work has shown that SSEA-1 possibly functions to bind and modulate these growth
factors [91], and when this is supplemented with the prominent expression of SSEA-1 in the
basalis epithelium, it is conceivable that these cells are a component of the endometrial-epithelial
stem/progenitor cell niche. However, this study has not demonstrated any other stem cell properties
of the SSEA1+ epithelial cells and their in vivo tissue reconstitution ability is also not yet known.
More recent work has described some SSEA1+ cells to also be located in the LE, thus the expression is
not strictly limited to the basalis [85]. The other criticism of SSEA1+ cells being progenitors is their
relative abundance in the basalis and in the PM endometrium. ASCs are expected to be rare cells
in a given tissue. However, the huge regenerative requirement of the human endometrium may
require a greater number of ASCs. Moreover, the SSEA-1+ cells may be committed progenitors and
more primitive ASCs may be a rarer subpopulation of SSEA1+ cells. These possibilities remain to be
confirmed in future studies.
4.2. SOX9
SOX9 is a Wnt target transcription factor, and thus is located in the nucleus; it was first discovered
in patients with campomelic dysplasia [92]. SOX9 expression differentiates cells derived from all three
germ layers into a large variety of specialised tissues and organs, with roles in chondrogenesis [93,94],
male gonad development [95], neural crest development [96] and in the lower crypt region of the
intestinal epithelium [97]. SOX9 expressing cells detected by immunohistochemistry (IHC) in normal
human endometrium were found to be present in significantly larger numbers in the proliferative
phase of the menstrual cycle when compared with the secretory phase [98]. Following this work,
another IHC study described SOX9 expression to be largely confined to the basal epithelial cells
throughout the cycle, with significantly greater numbers of epithelial cells expressing nuclear SOX9 in
the basalis (46.2–52.3%) over the functionalis (8–12.1%) glands. The PM endometrium demonstrated
the highest SOX9 immunostaining out of the pre/PM endometrial samples, with over 75% of PM
epithelial cells expressing nuclear SOX9 [13].
This paper concluded that nuclear SOX9 co-localised with SSEA-1 and nuclear β-catenin,
suggesting an activated Wnt pathway in the basal glands of premenopausal endometrium, could
function by maintaining the SSEA-1+ cells in a less-differentiated state, representing the endometrial
stem/progenitor cell compartment of the stem cell niche, playing an important role in homing stem
cells [13]. It was also concluded that high levels of nuclear SOX9 observed in the PM endometrial
epithelial cells may function as a checkpoint to prevent hyperplasia, as loss of SOX9 in the intestinal
epithelium leads to hyperplasia [99]. Although nuclear SOX9 may mark a potential primitive cell
population in the endometrium, due to the nuclear location, SOX9 is obviously not a suitable marker
to isolate these cells for further functional studies. The authors further concluded that nuclear SOX9,
containing basalis endometrial epithelial cells, can be isolated for functional studies using the surface
marker SSEA-1 [13], and their subsequent in vitro experiments demonstrated these epithelial cells to
have high telomerase activity and superior ability to generate endometrial gland-like organoids in
3D culture [13]. As mentioned above for SSEA-1, the number of cells containing nuclear SOX9 in the
endometrial epithelium is greater than the expected abundance for an ASC population.
4.3. Nuclear β-Catenin
The canonical Wnt/β-catenin signalling pathway is involved in cell fate determination.
Wnt signalling pathway activation causes β-catenin to enter the nucleus, where it regulates the
Int. J. Mol. Sci. 2018, 19, 3240 11 of 26
transcription of target genes [100]. In the absence of Wnt signalling, β-catenin is dislocated from the
nucleus. In the highly regenerative intestinal epithelium, nuclear β-catenin is highly expressed in the
stem cell region of the intestinal crypt [97,101]. It functions to maintain organisation of the intestinal
epithelial cells and is crucial for maintaining an undifferentiated state, evidenced by diminished activity
in differentiated cells. Loss of nuclear β-catenin in the intestinal crypt results in rapid degeneration of
epithelial cells [101,102].
In the endometrium, the Wnt/β-catenin pathway has been shown to be active in pre and PM
endometrial cells [92] and is implicated in regulating the menstrual cycle, with increased nuclear
β-catenin expression seen in proliferating endometrial epithelial cells [103–105].
Nuclear β-catenin has been identified in a sub population of epithelial cells in the basalis layer
of the endometrium co-expressed with SSEA-1 and SOX9, where the stem cell niche is postulated to
reside [13]. In this study, nuclear β-catenin expression was restricted to occasional basal glandular
epithelial cells, and a similar expression pattern to co-localised SOX9 and β-catenin expression in the
intestine was also demonstrated in the endometrium.
Although the published literature on nuclear β-catenin in the endometrium is limited, it does
suggest that the endometrial epithelial cells in the basalis which express it could have stem cell
properties. This data is in keeping with the current understanding of stem cell activation in the
intestinal epithelium.
4.4. N-Cadherin
Data from a Wnt-associated gene profiling study of the endometrium [92] identified N-cadherin
(gene CHD2) to be enriched in the postulated stem/progenitor cell rich postmenopausal endometrium.
Given the known importance of Wnt signalling in stem cell biology, the authors investigated the
cell surface marker N-cadherin to determine if it could be a potential marker of the endometrial
epithelial progenitors [84]. N-cadherin protein was shown to be expressed in 16.7% (range 3.7–36.7%)
of epithelial cell adhesion molecule (EpCAM)+ endometrial epithelial cells sorted with FACS, and
in 20.2% (range 8–35.5%) of the epithelial cells sorted with magnetic beads. When colony forming
assays were utilised to assess the enrichment of epithelial progenitors, larger clones and significantly
higher median cloning efficiency were observed in the N-cadherin+ cells. These clones were large and
densely packed, with small cytokeratin-positive cells and a high nuclear:cytoplasmic ratio. When serial
cloning was undertaken, N-cadherin+ cells generated clones from freshly isolated suspensions and
samples underwent up to three rounds of serial cloning, and were also differentiated into cytokeratin+
gland-like epithelial structures with a lumen in 3D Matrigel. N-cadherin was found by IF to be strongest
in the basalis glands adjacent to the myometrium, and rarely co-localised with Ki-67, indicating a
quiescent phenotype. Although some overlap of expression was seen, SSEA-1+ cells were described
to be phenotypically distinct from N-cadherin+ cells, suggesting a potential epithelial hierarchy [84].
Importantly, the authors reported no N-cadherin expression in the LE. Two further IHC studies were
also published in the same year. The first compared infertile patients with fibroids, to fertile controls,
using IHC and qRT-PCR [106,107]. This showed that N-cadherin was lower in the LE in the mid
secretory endometrium of infertile women when compared to fertile controls, but no significant change
was demonstrated in either the immuno-expression or the mRNA. The IHC staining demonstrated by
Makker et al (LE expresses strongest levels) [106] is in stark contrast to the IF staining presented in the
Nguyen et al study (basalis adjacent to the myometrium expresses strongest levels) [84].
Therefore, the published studies on endometrial N-cadherin seem to report major conflicting
differences. However, these studies have reported on N-cadherin expression in a variety of patient
populations (healthy and pathological) using different techniques; the exact clones identified by
different anti-N-cadherin antibodies were inconsistent and this makes it difficult to draw conclusions
from the available endometrial N-cadherin data. However, the cells expressing the N-cadherin epitope
described by Nguyen et al may have some progenitor activity, and their exact position in the human
endometrial epithelial differentiation hierarchy is yet to be confirmed in a functional study and in
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the context of the recently proposed endometrial epithelial 3D architecture [86]. Finally, similar to
SSEA1, the N-cadherin expressing cells are also present in a greater number than what is expected for
an ASC population.
5. Examining Endometrium for the Expression of Putative Stem Cell Markers That Were
Identified to be Expressed in the Epithelial Stem Cells (ESCs), or Stem Cells of Different Tissues
(e.g., OCT4, Mushashi-1, LGR5, Notch1/numb)
5.1. OCT-4
OCT-4 has been proposed as a marker of pluripotent human ESCs and some ASCs. Although
the expression of OCT-4 has regularly been associated with primitive cell types by many authors,
it is important to appreciate that the synergistic expression of the classical pluripotency gene triad,
OCT-4, NANOG and SOX2 is required to maintain pluripotency. OCT-4 was seen in some endometrial
samples by IHC, and in all endometrial samples by reverse transcriptase-polymerase chain reaction
(RT-PCR) with variable expression in the human endometrium [108]. Close scrutiny of the pictures
presented in this manuscript reveal that OCT-4 is not expressed in the epithelial cells, but appears to be
seen rarely in some stromal cells or blood vessels. The micrographs of the immuno-staining were not
supported by further confirmatory data using a secondary method. The authors simply concluded that
OCT-4 staining is present and is mostly expressed in the stromal compartment [108]. In a subsequent
study, OCT-4 was found not to be differentially expressed during the menstrual cycle in women and
is, therefore, proposed to be uninfluenced by hormones [109]. OCT-4 has also been located in some
mouse LRCs in the deeper endometrial stroma, co-localising with c-KIT [82]. Therefore, further work
is needed (using a reliable antibody, specific to human OCT4a antigen) to examine the cell-specific
expression in the human endometrium, since OCT4a is the particular antigen associated with an
undifferentiated phenotype. Therefore, we can conclude that in the present time, there is no robust
evidence to suggest OCT-4 expressing cells to be relevant to the endometrial ASC population.
5.2. Musashi-1
Musashi-1 is an RNA-binding protein in neural stem cells and an intra-cellular epithelial
progenitor cell marker that regulates self-renewal signalling pathways. The protein is expected
to assume an intracellular location, and thus will not be suitable for use in isolation of the cells that
express it for functional studies. Musashi-1 was immunolocalised to single epithelial cells, and small
clusters of stromal cells in human endometrium [110]. The authors describe the staining as nuclear
and cytoplasmic, but the representative figures presented in the manuscript only demonstrated
cytoplasmic staining. IF images showed Musashi-1 to be co-localised with its molecular target, Notch1,
and telomerase. Musashi-1 positive cells were mainly found in the basalis in the proliferative stage of
the menstrual cycle (when compared to the secretory stage), suggesting their possible stem/progenitor
cell function. Stromal Musashi-1 positive cells were not found in a perivascular location, although some
were in a peri-glandular region, a similar location to some stromal LRC in mouse endometrium [80].
More recently, Musashi-1 expression has been found in the neonatal endometrium from the 12th
week of gestation, with the number of positive cells decreasing with increasing gestational age. In the
reproductive endometrium, Musashi-1 staining was seen in dispersed single cells and in stromal cell
groups adjacent to myometrium [111].
In summary, there is only limited data on cytoplasmic and nuclear IHC staining for Musashi-1 in
the endometrium, without any functional studies confirming the stem cell properties of these cells.
To date, no further confirmatory work has been undertaken since the preliminary publication in 2008.
Therefore, Musashi-1 is yet to be proven as an endometrial ASC marker.
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5.3. Notch1/Numb
The family of Notch proteins are ligand-dependent transmembrane receptors that transduce
extracellular signals responsible for cell fate and differentiation in a multitude of cellular systems and
niches [112–115]. Notch1 is a heterodimeric, 300-kDa type 1 transmembrane receptor which mediates
signaling induced by cell-to-cell contact [116]. Numb is an inhibitory regulator of Notch1 signaling
that acts by promoting the ubiquitination and degradation of the Notch1 intracellular domain [114].
Positive Notch1 immuno-staining has been found to be concentrated in the cytoplasm of
endometrial epithelial cells, whereas very weak staining has been observed in the stromal cells.
This immuno-expression was dynamic in the endometrium, with higher Notch1 in the proliferative
phase than in the secretory phase in some studies [114,117], although the reverse was reported
in others [115], while no significant difference was observed between the proliferative phase in
pre-menopausal and postmenopausal samples. Interestingly, the maximal staining intensity was seen
in the mid secretory receptive phase of the menstrual cycle [118]. Strong cytoplasmic immunostaining
for Numb was limited to the epithelial cells and very weak staining was observed in the stroma.
Contrasting results have been reported, suggesting either consistent levels across the menstrual
cycle [114] or decreased immuno-expression in the mid secretory phase [118]. These studies
only utilized single technique (IHC) without any secondary confirmatory techniques or functional
work [114].
The studies that considered Notch1 as a stem cell marker (showing maintenance of cells in an
undifferentiated state) used both IHC and qPCR to confirm the presence of Notch1 in endometrial
biopsies, and the clones containing Notch1 were able to differentiate into multiple lineages [119].
However, due to their intracellular location, Notch1/Numb are not suitable markers for isolating the
potential ASCs for further study.
5.4. MSCA-1
MSCA-1, a bone marrow-derived MSC surface marker, has been identified to be identical to
Tissue Non-specific Alkaline Phosphatase (TNAP) [120–125]. When ESC’s differentiate, the expression
of TNAP decreases [42]. TNAP is expressed on endometrial perivascular cells, the proposed location
of endometrial MSC-like cells [42]. The proportion of W8B2+CD146+ endometrial stromal cells was
compared to the proportion of CD146+PDGFRβ+ MSC-like cells found in the human endometrium,
and these were very similar, leading to the conclusion that endometrial MSC-like cells express TNAP.
Combined with CD146, this ectoenzyme was proposed to be a suitable marker for the isolation from the
EpCAM− endometrial stromal population. Due to TNAP being exclusively expressed in the CD146+
subset, but not on other MSC-like/fibroblast-like cells, it would appear that TNAP is developmentally
expressed on MSC/pericyte progenitor cells and is down-regulated during further differentiation.
Not only was TNAP expressed on the endometrial perivascular cells, but immuno-staining was
detected on endometrial epithelial cells at the apical luminal surface [25]. This has led to TNAP also
being proposed as a marker for the isolation of a subset of endometrial glandular epithelial cells.
However, the assessment of the ability of TNAP expressing cells to recapitulate endometrial tissue
in animal models, and their multilineage potential, would require these cells to be sorted on the
basis of their expression of TNAP, as well as EPCAM. Therefore, TNAP may not suitable as a single
marker isolation protocol for endometrial MSC. However, the fact that TNAP is expressed in the cells
of stromal and epithelial compartments is interesting, and if further studies demonstrate that cells
expressing TNAP from both fractions possess stem cell characteristics, it may be a common marker for
cells involved in the endometrial regeneration process, and a good therapeutic target. Consequently,
further studies are warranted in this area.
Int. J. Mol. Sci. 2018, 19, 3240 14 of 26
5.5. LGR5
Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5) is a transmembrane
receptor [126] characterised by a large leucine-rich extracellular domain [126], belonging to a family of
glycoprotein hormone receptors [127]. Little was known about mammalian LGR5 before 2007 [128]
when it was discovered by researchers seeking an intestinal stem cell marker [129]. Subsequently, in
the human endometrium, by using RT-PCR, LGR5 gene was found to be expressed in 26 full thickness
mid proliferative to late secretory phase samples [130]. Substantial differences were discovered in
expression levels of individual women, but no variation was observed throughout the menstrual cycle,
therefore suggesting it was not hormonally regulated. This study was followed by a mouse study
demonstrating that: murine lgr5 gene is dynamically regulated in endometrial epithelium expressed
only in immature and ovariectomised mice, and is down-regulated by oestrogen. All of this evidence
alludes to a hormonal regulation, and for LGR5 to be lost with differentiation (such as acquiring
hormonal responsiveness, refer to Figure 2) [127]. More recently, a review paper proposed LGR5
to be a potential stem cell marker in the human endometrium. The authors also included original
data in this review, using IHC to show a population of stromal and epithelial cells stained by an
anti-human LGR5 antibody and LGR5+ cells mainly located in the perivascular regions [131]. In this
review, further original data from telomapping (a type of confocal quantitative fluorescence in situ
hybridisation that displays the gradient of telomere length in a given adult tissue) to identify cells with
the longest telomeres was also included. The authors subsequently claimed that LGR5 mRNA signal
was present in some of the cells containing the longest telomeres, suggesting that LGR5 expressing cells
are associated with a long telomere phenotype. Notably, this statement was made without supporting
data. No menstrual cycle differences were reported with regards to the expression of LGR5 protein.
The authors concluded that perhaps LGR5 could be considered as a universal stem cell marker and
possibly a marker of ASCs in the human endometrium [131]. Although this review presented some
limited original work on LGR5 mRNA and protein, without the provision of detailed methodology
(e.g., information on the exact antibody used) [132], scientific scrutiny is not possible for the robustness
of that data. Since the specificity of the available anti-human LGR5 antibodies are in considerable
doubt, the claim that LGR5-expressing cells identified by IHC are ASCs needs further investigation
using more suitable methods. The subsequent publication from the same group described xenografting
the isolated LGR5+ cells using an anti-human LGR5 antibody into a mouse model [132] to determine
their functional relevance. However, the location of the LGR5+ cells in the intact human endometrium
using the same anti-human LGR5 antibody was not described. Whether this study used the same
antibody that they had used in their previous review is also unclear [131]. Human LGR5+ epithelial
and stromal cells from endometrial biopsies (not full thickness endometrium, and thus will contain
only the functionalis layer including LE) were sorted, according to their surface expression of LGR5,
using an antibody (of unconfirmed specificity) by FACs, and were phenotypically characterised by
flow cytometry with haematopoietic and mesenchymal markers. These LGR5-enriched cells were
labelled and injected under the kidney capsule of immunocompromised mice. The authors reported
LGR5+ cells in the human endometrium to constitute 1.08 ± 0.73%, and 0.82 ± 0.76% of the total cells
in the epithelial and stromal compartments respectively. LGR5-enriched cells showed an abundant
expression of CD45 (a mature leucocyte marker) and no expression of more primitive surface markers
CD31, CD34, CD133, CD73, and CD90. However, co-expression of LGR5+ with the macrophage marker
CD163 was detected. The tissue recapitulation resulted in a weak endometrial reconstitution, and
transcriptomic profiling revealed new attributes for LGR5+ cells related to their putative hematopoietic
origin. Authors concluded that LGR5 was unlikely to be a universal stem cell marker [132], opposing
their previous proposal [131]. They further stated that LGR5+ cells appeared to be recruited from blood
to be part of the stem cell niche at the perivascular microenvironment, to activate the endogenous
niche [132].
When considering the available evidence, the mouse lgr5 studies may not translate well to
humans due to obvious species-specific differences in their endometrial biology. The initial study
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examining human LGR5 mRNA level did not attempt to ascertain the location of the endometrial LGR5
expression [131]. The specificity of all presently available anti-human LGR5 antibodies to identify the
protein are not confirmed, and are of considerable doubt [133].
To overcome the above deficiencies in the literature, earlier this year, the gold standard
method of in situ hybridisation (ISH) was utilised alongside qRT-PCR, IHC and in silico analysis
of published endometrial microarray datasets to conclusively examine the cellular location of LGR5
expression in full thickness normal human endometrium [85]. LGR5 expression was limited to
the epithelial compartment of the endometrium, with high LGR5 expressing cells seen in the
endometrial LE and in the stratum basalis; the LE expressed significantly higher levels of LGR5
than all other epithelial compartments. The dynamic spatiotemporal pattern of LGR5 expression
suggested hormonal regulation, with a reduction in LGR5 expression in the secretory phase
(with ISH) in the luminal and functionalis epithelium respectively. Endogenous and exogenous
progestogens inhibited LGR5 expression in the endometrium both in vivo and in vitro in explant
culture. When endometrial samples of women taking synthetic progestogen treatment (progesterone
only pill, ‘POP’, or levonorgestrel-releasing intrauterine system, ‘LNG-IUS’) were compared with
the samples of women not on any treatment, a significant reduction of LGR5 mRNA levels was
observed. Data was further confirmed by analysing previously published microarray datasets.
The epithelial compartment-specific expression pattern of LGR5 in the full thickness endometrium
prompted the novel theory that more than one epithelial stem/progenitor cell pool could exist in
the human endometrium; one residing in the basalis (SSEA-1++/SOX9++/LGR5+) supporting the
massive regeneration of the functionalis after menstrual shedding or parturition; while the other
(LGR5++/SSEA-1+/SOX9+) supports the embryo-implantation process, and maintains the LE cells that
are likely to be lost on a daily basis [85]. However, this study was an observational study without any
functional data. It is therefore important in the future, when a reliable anti-human LGR5 antibody is
available, for further work to be carried out to assess the LGR5-enriched cells from the endometrium
for stem cell function.
5.6. Telomerase
Telomerase is an RNA-dependent DNA polymerase enzyme responsible for synthesising and
maintaining telomeres that exists at the ends of all linear chromosomes (Reviewed in Hapangama et al.,
2017 [134]). The expression of telomerase in human cells is essential for maintaining cellular integrity
and immortalization. TERT is the catalytic subunit of telomerase holo-enzyme, and has been shown
to be expressed in cells with self-renewing potential, including stem cells [135]. TERT+ intestinal
epithelial cells are considered to be intestinal stem cells which are quiescent and are regenerated in
response to tissue injury [136].
In the human endometrium, telomerase activity is limited mainly to the glandular epithelium [137].
Isolated SSEA-1+ basalis progenitor epithelial cells grown in culture had a significantly higher
telomerase activity, longer mean telomere lengths and the ability to generate endometrial gland-like
structures than SSEA-1 depleted epithelial cells [13]. This study suggests that high telomerase activity
in SSEA-1+ epithelial cells may render this epithelial progenitor population to have an increased
replicative lifespan and possibly self-renewal, which are accepted stem cell properties.
Further evidence suggests telomerase activity to mark potential endometrial stem cells, comes
from a study where an increased number of epithelial cells co-expressed the ASC marker Mushashi-1
and telomerase reverse transcriptase (TERT) in the proliferative phase endometrial samples when
compared with normal secretory endometrium [110]. The reliability of anti-human telomerase
antibodies is known to be problematic; therefore, caution should be taken considering this
antibody-based telomerase study.
In a transgenic, green fluorescent protein (GFP) reporter mouse model, a small population of
mTERT+ presumed ASCs were identified in the endometrial luminal and glandular epithelial cells [138].
mTERT+ cells decreased in response to ovariectomy of the mouse, suggesting a role of ovarian steroid
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hormones in maintaining these cells. In other tissues such as bone marrow [139], mTERT-expressing
cells are considered to possess ASC qualities. The study, however, did not assess the functional ASC
activity of mTERT+ endometrial cells. Adequate telomerase activity is a prerequisite of proliferating
endometrial epithelial cells [140]; therefore, although there is evidence for telomerase activity in the
proposed ASC compartment in the human endometrium, further work is needed to clarify if telomerase
is a specific phenotypical ASC marker or is merely marking the activation status/proliferation of
the ASCs.
6. Involvement of Endometrial Stem Cells in Endometrial Proliferative Disease
The involvement of endometrial ASC in proliferative disease such as endometriosis and
endometrial cancer has been postulated [15]. Any recurrent or persistent disease of the premenopausal
endometrium, from heavy menstrual bleeding, infertility, or recurrent miscarriage should be
originating from abnormalities accumulated in the ASC population that is responsible for the regrowth
of a novel functionalis layer each month. Although the theoretical possibility that all endometrial
pathologies originate from aberrant endometrial ASCs is widely accepted, the direct evidence available
supporting this theory is scarce. Therefore, in this review, we have highlighted two endometrial
proliferative conditions, endometriosis and endometrial cancer, to highlight some of the interesting
data from the endometrial stem cell marker prospective.
6.1. Endometriosis
Endometriosis is a common, benign proliferative disease of the endometrium defined as having
endometrium-like tissue existing outside of the uterine cavity. One in 10 women of reproductive age
in the UK suffer from endometriosis, which is responsible for significant morbidity and places a huge
economic burden on the women, health services and society in general. Little is known about its
aetiology and pathogenesis and this prevents the formulation of novel treatments [141]. The ectopic
endometriotic tissue retains hormone responsiveness and may undergo inflammation, proliferation
and regeneration, and thus stem cells are thought to be involved in the pathogenesis. Leyendecker et al.
proposed that basalis endometrial cells enriched with progenitor potential are shed with menstruation
in women with endometriosis and these cells may give rise to ectopic lesions after retrograde
menstruation and trans-tubal migration in to the pelvic cavity [142]. The studies demonstrating
the expression of epithelial stem cell markers such as SSEA-1, SOX9 and nuclear β-catenin [13] and
Musashi-1 [110] in ectopic endometriotic lesions have suggested a possible direct involvement of ASCs
in endometriosis lesion formation. High telomerase activity is a feature of endometriosis [143] and
is also found in SSEA-1 expressing basalis progenitor epithelial cells [13]. Furthermore, Musashi-1
expressing endometrial epithelial cells have been shown to co-express telomerase catalytic subunit
(hTERT) [110]. The involvement of ASC’s in the pathogenesis of endometriosis is further supported by
increased expression of Numb and Notch1 in eutopic endometrium from patients with endometriosis,
when compared with controls, and could be associated with increased severity of the condition.
Knock down of Notch1 in human endometrial epithelial and stromal cells resulted in reduced
cellular proliferation and migration when injected into the peritoneal cavity of mice, and a reduced
size of resulting endometriotic lesion was observed, implicating Notch1 in the pathogenesis of
endometriosis [113]. An IHC study also reported increased Notch1 expression in adenomyosis. Studies
are awaited to determine the presence or the involvement of cells expressing N-cadherin and other
endometrial stromal ASC markers in ectopic endometriotic lesions formation. Interestingly, a recent
study which analysed synonymous and missense somatic passenger mutations has suggested that
ectopic endometriotic lesions contain clonal populations of epithelial cells originating from, presumably,
an ectopically situated epithelial ASC, whereas stromal cells may be continuously regenerated or
recruited over the course of disease [144,145]. This data presents a novel concept, in that the primary
cell type initiating and regulating the initiation as well as persevering the ectopic lesions could be
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the epithelial ASC and they may subsequently recruit stromal ASCs to create the endometrial niche.
Further studies are needed to examine this novel hypothesis.
6.2. Endometrial Cancer
Endometrial cancer is the most common gynaecological cancer with an increasing incidence.
In 2015 alone, 8984 new cases of endometrial cancer were diagnosed [146] and in 2016 [146], it was the
cause of 2360 deaths in the UK. With estimated increases of over 90% in annual costs for endometrial
cancer surgery, this places a huge burden on the NHS and society’s resources. Furthermore, alternative
therapy is urgently needed for the recurrent and metastatic disease that is resistant to both chemo and
radiotherapy. Specialised cancer cell sub-populations called cancer stem cells (CSC) are postulated to
be responsible for distant metastasis, cancer recurrence and resistance to chemo/radio therapy. High
telomerase activity is also implicated in cancer metastasis and CSC. CSC share many features with
adult tissue ASC in that they express telomerase, have self-renewal capabilities and higher proliferative
potential. SSEA-1 and Musashi-1 expressing potential endometrial epithelial ASCs from healthy
endometrium have been shown to have telomerase activity [13,110] and the malignant transformation
of these ASC is thought to initiate cancer. High levels of Musashi-1 expression has shown to be
associated with poor prognosis in endometrial cancer, suggesting that Musashi-1 expressing CSCs
are a possible therapeutic target [110,147,148]. SOX9 is also upregulated in endometrial cancer and
upregulation of SOX9 is a feature of the premalignant hyper-proliferative condition, endometrial
hyperplasia [98,149], suggesting an involvement of the basalis progenitor ASC in these conditions.
Using purely IHC, Xie and colleagues compared N-cadherin expression between patients with
endometrioid adenocarcinoma, and normal controls [150]. They showed that N-cadherin was
positive when brown/yellow particles were seen in the cytoplasm of a cell (again contradictory
to other published studies). For the 50 normal samples that were included in this study, the positive
expression rate for N-cadherin protein was 40.0% (8 weakly positive, 9 moderately positive, and 3
strongly positive) and the positive N-cadherin protein expression rate was statistically higher in
the endometrioid adenocarcinoma group compared to the normal controls. They also showed that
E-cadherin is not commonly expressed in the N-cadherin expressing cells, therefore, a transition may
exist between them [150]. An increase in Notch1 expression was reported in endometrial cancer
samples [115] in a study using IHC. Stromal Notch1 expression increased in endometrial carcinoma
with respect to hyperplasia and polyps. The cell fate determinant Numb, has also been reported to be
increased in endometrial cancer, compared to normal endometrium in a study using IHC [151], and the
immune-staining gradually increased in correlation with the advancing grade of the endometrial
cancer samples. However, functional studies are needed to examine the role of Notch1 and Numb in
endometrial carcinogenesis. However, there are no studies to date examining the expression or the
involvement of the other proposed normal endometrial ASC markers in endometrial cancer.
7. Conclusions
The human endometrium obviously contains ASCs that are responsible for its frequent, efficient
and scar-less regeneration. Recent work suggests that the main endometrial cell lineages, epithelium
and stroma, may develop independently; and neither cell types are likely to originate from bone
marrow-derived cells. There are many stromal and epithelial ASC markers proposed, with some
demonstrating in vitro stem cell properties, yet the in vivo tissue reconstitution ability of these cells has
either been poor or not yet fully examined. A summary of postulated endometrial stem cell markers
in the epithelia, stroma, and perivascular cell populations can be seen in Table 1. The differentiation
potential of the stromal and epithelial cells (isolated to ascertain their therapeutic utility) needs to be
fully confirmed in the future. The demonstration that there are epithelial cells expressing the described
ASC markers in endometrial proliferative conditions supports their involvement in the pathogenesis
of endometriosis and endometrial cancer, yet further studies are needed to ascertain the possibility of
targeting them for curative therapy.
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Table 1. Summary of postulated endometrial stem cell markers in epithelial, stroma, and perivascular cell populations.
Cell Type Location CD146/PDGFRβ SUSD2 SP LRCs SSEA-1 SOX9
Nuclear
β-Catenin N-Cadherin OCT4 Musashi-1
Notch/
Numb MSCA-1 LGR5 Telomerase
Epithelial
Luminal − − ? + + + − − + + ++
Functionalis − − ? − − − − + + − − +
Basalis − − ? ++ ++ + ++ + + − + +
Undefined +
Stromal
Functionalis +
Basalis +
Undefined + + +
Peri-vascular
Functionalis + + + ?
Basalis + + + +
References [22,42,43] [15,44] [1,45,47–53]
[2,80–
82]
[13,85,
87–91]
[13,92–
99]
[13,97,100–
105]
[84,92,106,
107]
[82,108,
109]
[80,110,
111]
[112–
119]
[25,42,112,
120–124]
[85,126–
133]
[13,110,
134–139]
Key: ++ strongly positive, + positive, − negative, ? existing evidence unclear.
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